Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares Eloxx Pharmaceuticals and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| Cumberland Pharmaceuticals | -34.40% | -28.81% | -9.25% |
Valuation and Earnings
This table compares Eloxx Pharmaceuticals and Cumberland Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | N/A | N/A | -$5.99 million | ($1.54) | -8.46 |
| Cumberland Pharmaceuticals | $44.52 million | 2.42 | -$2.84 million | ($0.71) | -10.11 |
Cumberland Pharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for Eloxx Pharmaceuticals and Cumberland Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 0 | 3 | 2 | 3.00 |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Eloxx Pharmaceuticals presently has a consensus target price of $38.33, indicating a potential upside of 194.19%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.
Risk & Volatility
Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.
Summary
Eloxx Pharmaceuticals beats Cumberland Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
